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Gastric retention will provide advantages such as delivery of drugs with narrow ab-
sorption windows in the small intestinal region, namely proximal parts of the gastroin-
testinal tract (stomach and/or duodenum). Pharmaceutical dosage forms which remain
in stomach for a prolonged period of time after oral administration and release the ac-
tive ingredient in a controlled manner are important for the delivery of a wide variety of
drugs (1-5).
Metoprolol succinate (MS) is a b1-selective adrenergic blocking agent (6). Since the
half-life of MS is ~3 to 4 h (7), multiple doses are needed to maintain a constant plasma
concentration for a good therapeutic response and improved patient compliance. It has
also been reported that MS absorption mainly takes place in the duodenum and jejunum
and is directly proportional to the dose available (8). A gastroretentive is particularly
useful for drugs that are primarily absorbed in the duodenum and upper jejunum seg-
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ments (9). MS is highly soluble throughout physiological pH. Drug solubility was 157
mg mL–1 in water (pH = 5.5) and 183 mg mL– 1 in 0.1 mol L–1 HCl solution (pH = 1.0). It
is therefore a suitable candidate with high solubility for a monolithic system (10).
The present study involves the design and optimization of a novel gastroretentive,
floating, swellable, controlled release tablet by combining three polymers with different
concentrations: sodium alginate (SA) – rapidly hydrating, rate controlling polymer, so-
dium carboxymethylcellulose (NaCMC) – gel forming agent, and magnesium alumino
metasilicate (MAS) – swelling controlling agent. Furthermore, calcium sulphate dihyd-
rate (CS) – cross linker, gel strength enhancer for SA, and sodium bicarbonate (SBC) as a
gas generating agent were also used. The combined effect of these polymers on the float-
ing behaviour and on in vitro release pattern of the MS has also been evaluated.
EXPERIMENTAL
Materials
Metoprolol succinate was received as a gift sample from Alembic Ltd., India. SA
was purchased from Anshul Agencies and NaCMC from Auqualon, India. CS was pur-
chased from JRS Pharma and SBC from S.D. Fine-Chem Ltd., India. MAS was purchased
from Gangwal Chemicals, India. All the other chemicals used were of analytical grade.
Methods
Calibration curves of MS were determined in 0.1 mol L–1 HCl and in methanol at
l = 222 nm (R = 0.9932 and 0.9982, respectively), using a UV-Visible spectrophotometer
(Lambda 25, Perkin-Elmer, USA). The calibration curve in 0.1 mol L–1 HCl was used for
dissolution studies while drug content was determined using the calibration curve in
methanol.
Preparation of MSGR tablets
MSGR tablets were prepared according to the composition of optimized batches
(Table I). MSGR tablets (200 mg) were prepared by the direct compression method. Ini-
tially, all ingredients were sieved through 425-mm sieve opening, weighed and mixed for
10 min in a planetary mixer (Kenwood PM 900, UK) at 10 rpm. The drug was mixed with
SA, NaCMC, MAS, SBC and CS. Finally, the MAS was added as a lubricant and mixed
for additional 2–3 min. Tablets were compressed on a tabletting machine (Minipress by
Clit, 10 stations, Chamunda Pharma Machinary Pvt. Ltd., India) fitted with a 10.4-mm
circular shaped standard concave punch with tableting force of (3.5 ± 0.5) ´ 103 kg.
Characterization of MSGR tablets
The prepared MSGR tablets were tested for physical characteristics, viz., mass varia-
tion, thickness (measured using a Vernier caliperse, Mitutoyo Corporation, Japan), hard-
ness (measured with a hardness tester, Erweka, Germany) and friability (determined us-
ing a Roche friabilator, Germany).
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Drug content
Accurately weighed MSGR tablets (10 tablets) were crushed to form a fine powder.
An accurately weighed quantity equivalent to 200 mg of MS was transferred to a 100-mL
volumetric flask. To this, 50 mL methanol was added and sonicated for 15 min. Volume
was made up to the mark with methanol. The solution was filtered through a 0.45-mm
filter and 1 mL of this solution was diluted to 50 mL with methanol. Absorbance was
measured at 222 nm.
In vitro dissolution studies
The release rate of MSGR tablets (n = 3) was determined with a USP dissolution ap-
paratus-II (paddle method) using 75 rpm speed and 900 mL of 0.1 mol L–1 HCl as disso-
lution medium at 37 ± 0.5 °C (11). A sample (10 mL of the solution) was withdrawn from
the dissolution apparatus (Electrolab, India) at regular time intervals up to 24 h (1, 2, 4,
6, 8, 10, 12, 16, 20 and 24 h) and replaced with the same volume of fresh dissolution me-
dium. The samples were filtered through a 0.45-mm membrane filter and diluted to a
suitable concentration with 0.1 mol L–1 HCl, and the absorbance of these solutions was
measured at 222 nm. Cumulative percentage of drug release was calculated using the
equation obtained from a standard curve.
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Table I. MSGR tablet composition
Formulation batch CS (%) SA (%) NaCMC (%) MAS (%)
MSO1 25.7 15.0 15.0 5.0
MSO2 35.7 10.0 10.0 5.0
MS03 25.7 20.0 10.0 5.0
MS04 25.7 10.0 20.0 5.0
MS05 15.7 20.0 20.0 5.0
MS06 35.7 10.0 15.0 –
MS07 25.7 20.0 15.0 –
MS08 25.7 10.0 15.0 10.0
MS09 15.7 20.0 15.0 10.0
MS10 35.7 15.0 10.0 –
MS11 25.7 15.0 20.0 –
MS12 25.7 15.0 10.0 10.0
MS13 15.7 15.0 20.0 10.0
MS14 25.7 30.0 – 5.0
MS15 25.7 – 30.0 5.0
MS16 30.7 15.0 15.0 –
CS – calcium sulphate dihydrate, SA – sodium alginate, NaCMC – sodium carboxymethylcellulose, MAS –
magnesium aluminium metasilicate.
All batches contain 33.3 % MS, 5.0 % SBC and 1 % magnesium stearate.
Total tablet mass is 600.0 mg.
In vitro buoyancy studies
The in vitro buoyancy studies were performed by measuring the floating lag times
according to the method of Rosa et al. (12). The tablets were placed in a 100-mL beaker
containing 0.1 mol L–1 HCl. The time required for the tablet to rise to the surface and
float was defined as the floating lag time (Flag).
Box-Behnken design
Statistical analysis of the Box-Behnken design batches was performed by multiple
linear regression analysis using SYSTAT 12. A Box-Behnken design was constructed to
study the effect of the independent variables, viz., the amount of SA (X1), the amount of
NaCMC (X2) and the amount of MAS (X3) on dependent variables like t25, t50, t75, Flag of
MSGR tablets.
RESULTS AND DISCUSSION
Physical characterization of the tablets
Tablet mass of all the formulations was found to be 600.0 ± 20.0 mg. Tablet thickness
was found to be 6.0 ± 0.1 mm. The hardness of the formulation was 70 to 90 N, indicat-
ing satisfactory mechanical strength. Percentage mass loss in the friability test was 0.2 to
0.5 % in all cases, which was an indication of good mechanical resistance of the tablet.
Tablets of all the prepared batches containing MS were found to be within 100.0 ± 5.0 %
of the labelled content, indicating content uniformity of the prepared formulations.
In vitro dissolution studies
Batch MS01 released 75 % of MS in 16 h with Flag of 48 s compared to batch MS13
which showed 75 % MS release in 16 h and the Flag of 540 s, and batch MS02 with a Flag
of 45 s and t75 of 10.2 h. Based on this data, batch MS01 was considered the best formula-
tion with desirable Flag, therefore this formulation was selected for factorial studies to
optimize the formulation and to study the effects of variables on the formulation (Tables
II and III). Prepared batches show variation in drug release due to different concentra-
tions of polymers used during their preparation (Fig. 1).
In vitro buoyancy studies
The results of in vitro buoyancy studies showed quick floating of the tablet within
2 min after placing the tablet in dissolution medium. Studies showed that no single poly-
mer individually was sufficient to produce buoyancy and integrity of the tablet. Flag va-
ried between 45 s to 15 min (Table II). Buoyancy mainly depended upon the quantity of
MAS and SBC. SBC of 5 % was found optimal with optimum integrity and controlled re-
lease profile of the drug from the tablet. MAS produces swelling of the tablet while SBC
has the ability to generate gas in the presence of hydrochloric acid, which gets entrap-
ped in the tablet. This leads to reduction in the density of the tablet, thereby producing
floating.
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In case of batches MS01 and MS02, the MAS quantity of 5.0 % produced Flag of 48 s
and 45 s, respectively, while in batch MS13, the quantity of MAS of 10.0 % produced
Flag of 540 s. The combination of polymer SA and NaCMC with CS showed integrity of
the system and produced buoyancy in a minimum of time. These hydrophilic polymers
hydrate and swell rapidly due to the imbibing of the gastrointestinal fluid by the tablet,
density of the tablet is lowered due to swelling and gas formation which helps in system
buoyancy.
419
S. P. Boldhane and B. S. Kuchekar: Development and optimization of metoprolol succinate gastroretentive drug delivery system,
















0 5 10 15 20
Time (h)
MS01 MS02 MS03 MS04
Fig. 1. MSGR tablets dissolution profile of batches MS01 to MS04. Mean ± SD, n = 3.
Table II. MSGR tablet-optimization batches in the Box-Behnken design
Batch code
Coded factor level#
t25 (min)a t50 (min)a t75 (min) a Flag (s)a
X1 X2 X3
MS01 0 0 0 180 ± 0 360 ± 0 960 ± 0 48 ± 1
MS02 –1 –1 0 132 ± 0 390 ± 0 612 ± 0 45 ± 1
MS03 1 –1 0 72 ± 0 228 ± 0 492 ± 0 >1800 ± 10
MS04 –1 1 0 48 ± 0 132 ± 0 360 ± 0 100 ± 4
MS05 1 1 0 110 ± 0 228 ± 0 450 ± 0 420 ± 3
MS06 –1 0 –1 48 ± 0 132 ± 0 348 ± 0 900 ± 6
MS07 1 0 –1 42 ± 0 108 ± 0 348 ± 0 1320 ± 13
MS08 –1 0 1 120 ± 1 336 ± 0 690 ± 0 900 ± 5
MS09 1 0 1 132 ± 1 330 ± 0 690 ± 0 390 ± 6
MS10 0 –1 –1 30 ± 1 48 ± 0 132 ± 0 780 ± 7
MS11 0 1 –1 72 ± 0 144 ± 0 360 ± 0 485 ± 4
MS12 0 –1 1 126 ± 0 348 ± 0 660 ± 0 320 ± 8
MS13 0 1 1 120 ± 0 270 ± 0 960 ± 0 540 ± 5
a Mean ± SD, n = 3.
Effect of the release modulating agent and swelling morphology
Effect of 5–10 % of MAS that increased the Flag and controlled the release profile
was studied. This was due to its extremely fine, porous nature, which allows the me-
dium to penetrate into the tablet through the small holes in its particles, leading to re-
duction in tablet density and producing swelling that increases the Flag. Medium uptake
by the tablet was determined in 0.1 mol L–1 HCl. MSGR tablet showed rapid hydration
and gelling intact up to 12 h.
Kinetics of drug release
Sigma Plot 10 was used for controlled release curve fitting to select the most appro-
priate model. The dissolution data for batch MS01 was fitted to the Bekker-Lonsdale,
first-order, Higuchi, Hixson-Crowell and Korsmeyer-Peppas models (13-15). The release
profile of the optimized batch MS01 fitted best to the first-order (R2 = 0.9868 and n =
0.543), indicating non-Fickian diffusion or anomalous transport, with release by diffu-
sion and swelling (combination of diffusion and erosion-controlled release). Neverthe-
less, the Korsmeyer-Peppas model has also shown a good coefficient of determination
(Table IV).
Box-Behnken design
The dependent variables chosen were the times required for 25, 50 and 75 % the cu-
mulative drug release and Flag; the results showed a wide variation (Table II). The data
clearly indicate that the values of t25, t50, t75 and Flag are strongly dependent on the in-
420
S. P. Boldhane and B. S. Kuchekar: Development and optimization of metoprolol succinate gastroretentive drug delivery system,
Acta Pharm. 60 (2010) 415–425.




–1 10 10 0
0 15 15 5
1 20 20 10
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Table IV. Kinetic modeling of drug release







dependent variables, viz. the amount of SA (X1), the amount of NaCMC (X2) and the
amount of MAS (X3). The resultant equations of all responses are given below:
t25 = –460.0 + 35.6X1 + 36.65X2 + 31.75X3 + 1.22X1X2 + 0.18X1X3 – 0.48X2X3 –
1.82X12 – 1.76X22 – 1.96X32 (R2 = 0.994) (1)
t50 = –284.25 + 12.9X1 + 47.7X2 + 79.8X3 + 2.58X1X2 + 0.18X1X3 – 1.74X2X3 –
1.83X12 – 2.79X22 – 3.51X32 (R2 = 0.989) (2)
t75 = –3960.75 + 301.05X1 + 293.25X2 + 106.8X3 + 0.90X1X2 + 0.0X1X3 + 0.72X2X3 –
10.41X12 –10.05X22 – 7.23X32 (R2 = 0.980) (3)
Flag = 1942.94.75 – 265.01X1 + 78.98X2 – 210.40X3 + 2.72X22 – 9.30X1X3 +
5.15X2X3 + 9.25X12 – 4.59X22 + 23.92X32 (R2 = 0.982) (4)
The values obtained for the coefficient of determination indicate a good fit. The data
demonstrate that both X1 and X2 affect the drug release (t25, t50 and t75). It may also be
concluded that the low level of X1 (amount of SA) and higher level of X2 (amount of
NaCMC) favour preparation of gastroretentive-sustained release MS tablets. High val-
ues of the X1X2 coefficient also suggest that the interaction between X1 and X2 had a sig-
nificant (p < 0.05) effect on t25, t50 and t75. It can be concluded that the drug release pat-
tern may be changed by appropriate selection of the X1, X2 and X3 levels. The results in
Table II reveal that batches MS02, MS08, MS09 and MS12 were close to the required at-
tributes of gastroretentive tablets in terms of t50, t75 and Flag, while batch MS01 was ideal
because of its controlled release profile for 16 h (960 min) with the desirable Flag of 48 s.
This was, therefore, considered the best formulation among all the prepared formulations.
The fitted equations relating to the response at t25, t50, t75 and Flag are shown in
equations (5–8):
t25 = 520 – 64.2X1 – 29.4X2 + 6.38X1X2 + 1.48X12 – 0.8X22 – 0.008X1X22 –
0.164X12X2 (R2 = 0.874) (5)
t50 = 2592.64 – 295.03X1 –155.83X2 + 21.3X1X2 + 7.95X12 – 0.206X22 –
0.07X1X22 – 0.552X12X2 (R2 = 0.867) (6)
t75 = 1481.78 – 385.45X1 – 13.46X2 + 37.62X1X2 + 13.75X12 – 9.65X22 +
0.18 X1X22 – 1.404X12X2 (R2 = 0.885) (7)
Flag = –4344.0 – 1858.8X1 + 2864.4X2 – 100.03X1X2 + 163.02X12 – 137.96X22 +
10.48X1X22 – 8.65X12X2 (R2 = 0.891) (8)
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Values of the coefficients of determination indicate a good fit. As seen from the
above equations, the individual factors, i.e., the amount of SA (X1) and the amount of
NaCMC (X2) had a negative effect on t25, t50, and t75 but in combination (X1X2) showed a
significant (p < 0.05) positive effect. In case of Flag, X1 showed a negative effect (decreas-
ing floating lag time) whereas X2 had a positive effect (increasing floating lag time)
while in combination they showed a negative effect (Fig. 2).
The following equations (9–12) show the effect of X1 and X3 on t25, t50, t75 and Flag:
t25 = 51.605 – 1.299X1 – 3.715X3 + 3.407X1X3 + 0.033X12 – 1.415X32 + 0.014 X1X32 –
0.113X12X3 (R2 = 0.942) (9)
t50 = 154.843 – 5.639X1 + 36.785X3 + 2.066X1X3 + 0.106X12 – 3.537X32 + 0.071X1X32 –
0.086X12X3 (R2 = 0.950) (10)
t75 = 287.407 – 1.763X1 – 179.24X3 + 34.446X1X3 + 0.062X12 – 0.464X32 –0.178X1X32 –
1.089X12X3 (R2 = 0.853) (11)
Flag = 154.912 + 79.046X1 – 375.13X3 – 12.53X1X3 – 1.420X12 + 80.113 X32 –
4.441X1X32 + 1.607X12X3 (R2 = 0.940) (12)
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Fig. 2. Response surface plots of the concentration of SA (X1) and NaCMC (X2), vs. a) t25, b) t50, c) t75
and d) Flag.
Individual factors X1 and X3 showed a negative effect on t25, t50, t75 but their combi-
nation showed a significant (p < 0.05) positive effect. Flag X1 showed a positive effect
but X3 had a negative effect.
The following equations (13–16) show the effect of X2 and X3 on Y (t25, t50, t75 and
Flag):
t25 = –185.00 + 28.20X2 + 43.60X3 – 1.04X2X3 – 0.80X22 – 3.640X32 + 0.164X2X32 –
0.036X22X3 (R2 = 0.974) (13)
t50 = –462.214 + 69.771X2 + 157.457X3 – 7.260X2X3 – 2.006X22 – 11.006X32 +
0.552X2X32 + 0.00X22X3 (R2 = 0.974) (14)
t75 = –2176.07 + 323.65X2 + 461.48X3 – 39.96X2X3 – 10.029X22 – 23.829X32 +
1.404X2X32 + 0.888X22X3 (R2 = 0.724) (15)
Flag = –584.786 + 238.529X2 + 409.84X3 – 51.35X2X3 – 8.934X22 – 29.734X32 +
2.50X2X32 + 1.050X22X3 (R2 = 0.724) (16)
The above equations indicate that individual factors X2 and X3 show a significant
(p < 0.05) positive effect on t25, t50, t75 and Flag but their combination had a negative effect.
It followed from the systematic study, using the Box-Behnken design, that the
amounts of SA, NaCMC and MAS had a significant effect (p < 0.05) on t25, t50, t75 and
Flag. Thus, by selecting a suitable concentration of the rapidly hydrating-rate-control-
ling polymer (SA), gel forming agent (NaCMC) and swelling-controlling agent (MAS),
the desired dissolution profile can be achieved.
CONCLUSIONS
The present study involved the design of a novel gastroretentive floating and
swellable, controlled-release, tablet of MS. Its comprised the release-rate-controlling hy-
drophilic polymers, a release modulator and a gas generating agent. Upon administra-
tion, the MSGR tablet was hydrated and swelled rapidly due to imbibition of the gastro-
intestinal fluid; subsequent gas generation helped the system buoyancy and the desired
release profile. Optimized batch formulation MS01 showed buoyancy with Flag time less
than one min (48 s) and remained floating for 16 h. Minimum floating time and higher
percetange of swelling of the MS01 formulation is required to increase its residence time
in the stomach and eventually improve the extent of bioavailability. The present study
confirmed the test of the suitability of gastroretentive platform technology developed
for the MSGR tablet without changing any excipients and process parameters. The opti-
mized batch MS01GR tablet, prepared using novel combinations of SA, NaCMC and
MAS, can be successfully employed as a once-a-day oral controlled release drug deli-
very system.
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S A @ E T A K
Razvoj i optimizacija sustava za isporuku metoprolol sukcinata
sa zadr`avanjem u `elucu
SANJAY P. BOLDHANE i BHANUDAS S. KUCHEKAR
U radu je opisan razvoj sustava za isporuku metoprolol sukcinata (MS) s kontrolira-
nim osloba|anjem i produljenim vremenom zadr`avanja u `elucu (GR), u svrhu pobolj-
{anja bioraspolo`ivosti. Primijenjen je Box-Behnkenov model, a kao zavisne varijable
izabrane su nove kombinacije natrijevog alginata (SA), natrijeve soli karboksimetilcelu-
loze (NaCMC) i magnezijevog aluminometasilikata (MAS). Vrijeme plutanja (Flag), t25,
t50, t75 i difuzijski eksponent kao zavisne varijable otkrili su da koli~ina SA, NaCMC i
MAS ima zna~ajan u~inak (p < 0,05) na t25, t50, t75 i Flag. Pripravljenim tabletama odre-
|ena je masa, debljina, tvrdo}a, lomljivost, sadr`aj ljekovite tvari i sposobnost plutanja.
Osloba|anje MS pra}eno je 24 h. Rezultati pokazuju da je osloba|anje kontrolirano, a
vrijeme plutanja 16 h. Osloba|anje iz optimiranog pripravka MS01 slijedi kinetiku pr-
vog reda (R2 = 0,9868, n = 0,543), {to ukazuje na difuziju koja ne slijedi Fickov zakon ve}
anomalni transport difuzijom i bubrenjem.
Klju~ne rije~i: metoprolol sukcinat, zadr`avanje u `elucu, Box-Behnkenovo dizajniranje, plutaju}e
tablete, kinetika osloba|anja, kontrolirano osloba|anje
Piramal Health Care Limited, Mumbai-400063, India
Maharashtra Institute of Pharmacy, Pune-411038, India
425
S. P. Boldhane and B. S. Kuchekar: Development and optimization of metoprolol succinate gastroretentive drug delivery system,
Acta Pharm. 60 (2010) 415–425.
